Ceftazidime-Avibactam for the Treatment of Carbapenem-Resistant Infections in Patients With Liver Cirrhosis.

Background: Carbapenem-resistant (CRKP) infections in patients with cirrhosis represent a significant therapeutic challenge as they are associated with poor outcomes due to high rates of treatment failure, and frequently induce liver decompensation.

Aims: To evaluate treatment failure and in-hospital mortality in two cohorts of patients with cirrhosis and with CRKP infections treated with antibiotic regimens including or excluding Ceftazidime-avibactam.

Methods: Data from hospitalized patients with liver cirrhosis and CRKP infections were extracted and retrospectively analyzed.